Evolving Cognitive Dysfunction in Children with Neurologically Stable Opsoclonus-Myoclonus Syndrome.

cognitive dysfunction neurodevelopment opsoclonus–myoclonus syndrome

Journal

Children (Basel, Switzerland)
ISSN: 2227-9067
Titre abrégé: Children (Basel)
Pays: Switzerland
ID NLM: 101648936

Informations de publication

Date de publication:
19 Aug 2020
Historique:
received: 21 07 2020
revised: 09 08 2020
accepted: 13 08 2020
entrez: 23 8 2020
pubmed: 23 8 2020
medline: 23 8 2020
Statut: epublish

Résumé

Cognitive and acquired neurodevelopmental deficits have been reported in children with opsoclonus-myoclonus syndrome (OMS) and are known to be associated with more severe and relapsing disease course. However, there is a paucity of data regarding cognitive dysfunction in children with stable neurological disease. We report three children with OMS and evolving cognitive dysfunction in the context of a mild disease course. The children's ages at disease onset were between 17 and 35 months and they were followed up for 4-10 years. Neuroblastoma was identified in one child. OMS severity scores ranged between 8 and 12/15 at presentation. They underwent immunotherapy and all were in remission by 7 months (range 4-13 months), with treatment maintained for 1 year. One child remained relapse-free, while two others had one clinical relapse each and were immunotherapy-responsive again. In all cases, evolving cognitive dysfunction was reported despite being in remission and stable off treatment for a median of 20 months (range of 12-31 months; two OMS scores of 0/15 and one of 2/15). In children with OMS who have completed treatment and have made full or near full neurological recovery, concerns remain regarding long-term outcome in terms of future learning and cognitive development.

Identifiants

pubmed: 32824925
pii: children7090103
doi: 10.3390/children7090103
pmc: PMC7552772
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Brain. 2011 Aug;134(Pt 8):2197-221
pubmed: 21784775
Curr Opin Pediatr. 2010 Dec;22(6):745-50
pubmed: 20871403
Neurology. 2018 Aug 21;91(8):e714-e723
pubmed: 30045961
Eur J Paediatr Neurol. 2010 Mar;14(2):156-61
pubmed: 19423368
J Pediatr Psychol. 2009 May;34(4):406-18
pubmed: 18794190
Pediatr Neurol. 2014 Oct;51(4):515-21
pubmed: 25266614
Pediatrics. 2005 Oct;116(4):901-7
pubmed: 16199699
Dev Med Child Neurol. 2015 Mar;57(3):265-72
pubmed: 25290446
Annu Rev Psychol. 2009;60:173-96
pubmed: 19035823
Neurology. 2004 May 11;62(9):1526-32
pubmed: 15136676
Behav Neurol. 2017;2017:1463570
pubmed: 29434433
J Pediatr Oncol Nurs. 2005 Jan-Feb;22(1):8-19
pubmed: 15574722
Dev Med Child Neurol. 2020 Jul 22;:
pubmed: 32696984
Pediatrics. 2011 Aug;128(2):e388-94
pubmed: 21788225
Front Neurosci. 2011 Mar 11;5:25
pubmed: 21441995
J Pediatr. 2001 Oct;139(4):552-9
pubmed: 11598603
Pediatrics. 2008 Jun;121(6):1155-64
pubmed: 18519485
Pediatrics. 2002 Jan;109(1):86-98
pubmed: 11773546
Paediatr Perinat Epidemiol. 2009 May;23(3):186-98
pubmed: 19775380
BJOG. 2018 Jan;125(1):16-25
pubmed: 29024294

Auteurs

En Lin Goh (EL)

Oxford University Clinical Academic Graduate School, Medical Sciences Division, University of Oxford, Oxford OX3 9DU, UK.
Department of Paediatrics, Children's Hospital Oxford, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.

Kate Scarff (K)

Department of Clinical Neuropsychology, Oxford Psychological Medicine Centre, Oxford OX3 9DU, UK.

Stephanie Satariano (S)

Children's Neuroscience Centre, Evelina London Children's Hospital, Guy's and St Thomas' NHS Trust, London SE1 7EH, UK.

Ming Lim (M)

Children's Neuroscience Centre, Evelina London Children's Hospital, Guy's and St Thomas' NHS Trust, London SE1 7EH, UK.
Department of Women and Children's Health, Faculty of Life Sciences, King's College, London SE1 7EH, UK.

Geetha Anand (G)

Department of Paediatrics, Children's Hospital Oxford, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.

Classifications MeSH